Daiichi Sankyo Pays $39m To Settle U.S. Kickback Allegations
This article was originally published in PharmAsia News
The U.S. subsidiary of major Japanese company Daiichi Sankyo has agreed to pay a $39 million fine, plus fees and costs, to the U.S. Government and state Medicaid programs in a civil settlement to resolve allegations it paid kickbacks designed to induce physicians to prescribe certain of its drugs.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.